Dr Reddy’s purchases 42 ANDAs in US to augment injectables portfolio

By PharmaCompass

2019-04-18

Impressions: 135 Article

Indian drug major Dr Reddy’s Laboratories announced it has acquired a portfolio of 42 abbreviated new drug applications (ANDAs) in the US.

The portfolio includes more than 30 generic injectable products. These products will require a technology transfer and can be launched within the next one to two years. The total addressable market for these products in the US is approximately US$ 645 million for the calendar year ending in December 2018.

“The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets,” Dr Reddy’s CEO Erez Israeli said in a statement.

“This transaction will help augment our injectables product portfolio in the US market and globally,” he added.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass